Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells

Vimla Band, Beth Y. Karlan, Vincent R. Zurawski, Bruce A. Littlefield

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OVCA 433 human ovarian carcinoma cells secrete both mammalian plasminogen activators (PAs) urokinase (UK) and tissue‐type PA (tPA). Treatment of cells with 4β‐phorbol‐12‐myristate‐13‐acetate (PMA), a stimulator of protein kinase C (PKC), leads to large increases in the secretion rates of both PA types. PA stimulation by PMA is time‐ and concentration‐dependent, with maximal effects occurring between 12 and 24 h at PMA concentrations of 1–10 ng/ml. The PMA effect is mimicked by mezerein, another known PKC stimulator, but not by 4α‐phorbol or 4α‐phorbol‐12,13‐didecanoate, two phorbol compounds that do not stimulate PKC. PA activity is virtually unaffected by 1‐oleoyl‐2‐acetylglycerol (OAG), a synthetic diacylglycerol that stimulates PKC in vitro but has variable effects on whole cells. PMA stimulation of PA activity is blocked by both actinomycin D and cycloheximide, indicating requirements for new RNA and protein synthesis. When analyzed individually, the relative PMA‐induced increases in UK and tPA activities are identical. Increased UK activity is fully accounted for by increased UK antigen secretion, whereas increased tPA secretion accounts for only about one‐half of the increased tPA activity. Similarly, PMA induces large increases in steady‐state UK mRNA levels, while its effects on tPA mRNA levels are only modest. Thus, while increases in secretion rates and mRNA levels can completely account for UK stimulation, other mechanisms augmenting these processes must exist specifically for tPA. Since the relative increases in UK and tPA activities are identical despite the probable existence of multiple mechanisms contributing to tPA regulation, our data suggest the possibility of interrelationships between the two pathways such that equivalent degrees of UK and tPA activity stimulation are ultimately achieved.

Original languageEnglish (US)
Pages (from-to)106-114
Number of pages9
JournalJournal of Cellular Physiology
Volume138
Issue number1
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Phorbol Esters
Cells
Carcinoma
Protein Kinase C
Messenger RNA
Diglycerides
Dactinomycin
Cycloheximide
RNA
Antigens

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells. / Band, Vimla; Karlan, Beth Y.; Zurawski, Vincent R.; Littlefield, Bruce A.

In: Journal of Cellular Physiology, Vol. 138, No. 1, 01.01.1989, p. 106-114.

Research output: Contribution to journalArticle

@article{162e91a77bd54ad18ad2bcebcf6ce33f,
title = "Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells",
abstract = "OVCA 433 human ovarian carcinoma cells secrete both mammalian plasminogen activators (PAs) urokinase (UK) and tissue‐type PA (tPA). Treatment of cells with 4β‐phorbol‐12‐myristate‐13‐acetate (PMA), a stimulator of protein kinase C (PKC), leads to large increases in the secretion rates of both PA types. PA stimulation by PMA is time‐ and concentration‐dependent, with maximal effects occurring between 12 and 24 h at PMA concentrations of 1–10 ng/ml. The PMA effect is mimicked by mezerein, another known PKC stimulator, but not by 4α‐phorbol or 4α‐phorbol‐12,13‐didecanoate, two phorbol compounds that do not stimulate PKC. PA activity is virtually unaffected by 1‐oleoyl‐2‐acetylglycerol (OAG), a synthetic diacylglycerol that stimulates PKC in vitro but has variable effects on whole cells. PMA stimulation of PA activity is blocked by both actinomycin D and cycloheximide, indicating requirements for new RNA and protein synthesis. When analyzed individually, the relative PMA‐induced increases in UK and tPA activities are identical. Increased UK activity is fully accounted for by increased UK antigen secretion, whereas increased tPA secretion accounts for only about one‐half of the increased tPA activity. Similarly, PMA induces large increases in steady‐state UK mRNA levels, while its effects on tPA mRNA levels are only modest. Thus, while increases in secretion rates and mRNA levels can completely account for UK stimulation, other mechanisms augmenting these processes must exist specifically for tPA. Since the relative increases in UK and tPA activities are identical despite the probable existence of multiple mechanisms contributing to tPA regulation, our data suggest the possibility of interrelationships between the two pathways such that equivalent degrees of UK and tPA activity stimulation are ultimately achieved.",
author = "Vimla Band and Karlan, {Beth Y.} and Zurawski, {Vincent R.} and Littlefield, {Bruce A.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1002/jcp.1041380115",
language = "English (US)",
volume = "138",
pages = "106--114",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Simultaneous stimulation of urokinase and tissue‐type plasminogen activators by phorbol esters in human ovarian carcinoma cells

AU - Band, Vimla

AU - Karlan, Beth Y.

AU - Zurawski, Vincent R.

AU - Littlefield, Bruce A.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - OVCA 433 human ovarian carcinoma cells secrete both mammalian plasminogen activators (PAs) urokinase (UK) and tissue‐type PA (tPA). Treatment of cells with 4β‐phorbol‐12‐myristate‐13‐acetate (PMA), a stimulator of protein kinase C (PKC), leads to large increases in the secretion rates of both PA types. PA stimulation by PMA is time‐ and concentration‐dependent, with maximal effects occurring between 12 and 24 h at PMA concentrations of 1–10 ng/ml. The PMA effect is mimicked by mezerein, another known PKC stimulator, but not by 4α‐phorbol or 4α‐phorbol‐12,13‐didecanoate, two phorbol compounds that do not stimulate PKC. PA activity is virtually unaffected by 1‐oleoyl‐2‐acetylglycerol (OAG), a synthetic diacylglycerol that stimulates PKC in vitro but has variable effects on whole cells. PMA stimulation of PA activity is blocked by both actinomycin D and cycloheximide, indicating requirements for new RNA and protein synthesis. When analyzed individually, the relative PMA‐induced increases in UK and tPA activities are identical. Increased UK activity is fully accounted for by increased UK antigen secretion, whereas increased tPA secretion accounts for only about one‐half of the increased tPA activity. Similarly, PMA induces large increases in steady‐state UK mRNA levels, while its effects on tPA mRNA levels are only modest. Thus, while increases in secretion rates and mRNA levels can completely account for UK stimulation, other mechanisms augmenting these processes must exist specifically for tPA. Since the relative increases in UK and tPA activities are identical despite the probable existence of multiple mechanisms contributing to tPA regulation, our data suggest the possibility of interrelationships between the two pathways such that equivalent degrees of UK and tPA activity stimulation are ultimately achieved.

AB - OVCA 433 human ovarian carcinoma cells secrete both mammalian plasminogen activators (PAs) urokinase (UK) and tissue‐type PA (tPA). Treatment of cells with 4β‐phorbol‐12‐myristate‐13‐acetate (PMA), a stimulator of protein kinase C (PKC), leads to large increases in the secretion rates of both PA types. PA stimulation by PMA is time‐ and concentration‐dependent, with maximal effects occurring between 12 and 24 h at PMA concentrations of 1–10 ng/ml. The PMA effect is mimicked by mezerein, another known PKC stimulator, but not by 4α‐phorbol or 4α‐phorbol‐12,13‐didecanoate, two phorbol compounds that do not stimulate PKC. PA activity is virtually unaffected by 1‐oleoyl‐2‐acetylglycerol (OAG), a synthetic diacylglycerol that stimulates PKC in vitro but has variable effects on whole cells. PMA stimulation of PA activity is blocked by both actinomycin D and cycloheximide, indicating requirements for new RNA and protein synthesis. When analyzed individually, the relative PMA‐induced increases in UK and tPA activities are identical. Increased UK activity is fully accounted for by increased UK antigen secretion, whereas increased tPA secretion accounts for only about one‐half of the increased tPA activity. Similarly, PMA induces large increases in steady‐state UK mRNA levels, while its effects on tPA mRNA levels are only modest. Thus, while increases in secretion rates and mRNA levels can completely account for UK stimulation, other mechanisms augmenting these processes must exist specifically for tPA. Since the relative increases in UK and tPA activities are identical despite the probable existence of multiple mechanisms contributing to tPA regulation, our data suggest the possibility of interrelationships between the two pathways such that equivalent degrees of UK and tPA activity stimulation are ultimately achieved.

UR - http://www.scopus.com/inward/record.url?scp=0024588954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024588954&partnerID=8YFLogxK

U2 - 10.1002/jcp.1041380115

DO - 10.1002/jcp.1041380115

M3 - Article

VL - 138

SP - 106

EP - 114

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 1

ER -